-
1
-
-
0001511115
-
The influence of complicating diseases upon leukemia
-
Dock G. The influence of complicating diseases upon leukemia. Am J Med Sci 1904; 127 : 563-92.
-
(1904)
Am J Med Sci
, vol.127
, pp. 563-592
-
-
Dock, G.1
-
2
-
-
33947245441
-
History of oncolytic viruses: Genesis to genetic engineering
-
Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther; 15 : 651-9.
-
Mol Ther
, vol.15
, pp. 651-659
-
-
Kelly, E.1
Russell, S.J.2
-
3
-
-
59849122602
-
Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers
-
Sinkovics JG, Horvath JC. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch Immunol Ther Exp 2008; 56 Suppl 1 : 3s-59s.
-
(2008)
Arch Immunol Ther Exp
, vol.56
, Issue.SUPPL. 1
-
-
Sinkovics, J.G.1
Horvath, J.C.2
-
4
-
-
0016358317
-
Treatment of human cancer with mumps virus
-
Asada T. Treatment of human cancer with mumps virus. Cancer 1974; 34 : 1907-28.
-
(1974)
Cancer
, vol.34
, pp. 1907-1928
-
-
Asada, T.1
-
5
-
-
34548062828
-
Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow
-
Breitbach CJ, Paterson JM, Lemay CG, et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 2007; 15 : 1686-93.
-
(2007)
Mol Ther
, vol.15
, pp. 1686-1693
-
-
Breitbach, C.J.1
Paterson, J.M.2
Lemay, C.G.3
-
6
-
-
38649123395
-
Innate immunity, tumor microenvironment and oncolytic virus therapy: Friends or foes?
-
Stanford MM, Breitbach CJ, Bell JC, McFadden G. Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes? Curr Opin Mol Ther 2008; 10 : 32-7.
-
(2008)
Curr Opin Mol Ther
, vol.10
, pp. 32-37
-
-
Stanford, M.M.1
Breitbach, C.J.2
Bell, J.C.3
McFadden, G.4
-
7
-
-
33847319116
-
Cancer selective adenoviruses
-
Alemany R. Cancer selective adenoviruses. Mol Aspects Med 2007; 28 : 42-58.
-
(2007)
Mol Aspects Med
, vol.28
, pp. 42-58
-
-
Alemany, R.1
-
8
-
-
0033929057
-
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
-
Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6 : 821-5.
-
(2000)
Nat Med
, vol.6
, pp. 821-825
-
-
Stojdl, D.F.1
Lichty, B.2
Knowles, S.3
-
9
-
-
10744223476
-
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
-
Stojdl DF, Lichty BD, tenOever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003; 4 : 263-75.
-
(2003)
Cancer Cell
, vol.4
, pp. 263-275
-
-
Stojdl, D.F.1
Lichty, B.D.2
Tenoever, B.R.3
-
10
-
-
0027971239
-
In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy
-
Whitman ED, Tsung K, Paxson J, Norton JA. In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. Surgery 1994; 116 : 183-8.
-
(1994)
Surgery
, vol.116
, pp. 183-188
-
-
Whitman, E.D.1
Tsung, K.2
Paxson, J.3
Norton, J.A.4
-
11
-
-
0033565215
-
Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice
-
Gnant MF, Puhlmann M, Alexander HR, Jr., Bartlett DL. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. Cancer Res 1999; 59 : 3396-403.
-
(1999)
Cancer Res
, vol.59
, pp. 3396-3403
-
-
Gnant, M.F.1
Puhlmann, M.2
Alexander Jr., H.R.3
Bartlett, D.L.4
-
12
-
-
77955177289
-
Identification of genetically modified Maraba virus as an oncolytic rhabdovirus
-
Brun J, McManus D, Lefebvre C, et al. Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol Ther 2010; 18 : 40-9.
-
(2010)
Mol Ther
, vol.18
, pp. 40-49
-
-
Brun, J.1
McManus, D.2
Lefebvre, C.3
-
13
-
-
36049009021
-
Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963
-
Thorne SH, Hwang TH, O'Gorman WE, et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 2007; 117 : 3350-8.
-
(2007)
J Clin Invest
, vol.117
, pp. 3350-3358
-
-
Thorne, S.H.1
Hwang, T.H.2
O'Gorman, W.E.3
-
14
-
-
84863722111
-
Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferonbeta
-
Naik S, Nace R, Barber GN, Russell SJ. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferonbeta. Cancer Gene Ther 2012; 19 : 443-50.
-
(2012)
Cancer Gene Ther
, vol.19
, pp. 443-450
-
-
Naik, S.1
Nace, R.2
Barber, G.N.3
Russell, S.J.4
-
15
-
-
63949087329
-
Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses
-
Zamarin D, Martinez-Sobrido L, Kelly K, et al. Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther 2009; 17 : 697-706.
-
(2009)
Mol Ther
, vol.17
, pp. 697-706
-
-
Zamarin, D.1
Martinez-Sobrido, L.2
Kelly, K.3
-
16
-
-
42049121876
-
Enhancing poxvirus oncolytic effects through increased spread and immune evasion
-
Kirn DH, Wang Y, Liang W, et al. Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res 2008; 68 : 2071-5.
-
(2008)
Cancer Res
, vol.68
, pp. 2071-2075
-
-
Kirn, D.H.1
Wang, Y.2
Liang, W.3
-
17
-
-
66849141991
-
Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: In vitro and in vivo evaluation
-
Jin J, Liu H, Yang C, et al. Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation. Mol Cancer Ther 2009; 8 : 1387-97.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 1387-1397
-
-
Jin, J.1
Liu, H.2
Yang, C.3
-
18
-
-
36348950417
-
Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine
-
Ungerechts G, Springfeld C, Frenzke ME, et al. Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res 2007; 67 : 10939-47.
-
(2007)
Cancer Res
, vol.67
, pp. 10939-10947
-
-
Ungerechts, G.1
Springfeld, C.2
Frenzke, M.E.3
-
19
-
-
1442356959
-
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter
-
Dingli D, Peng KW, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004; 103 : 1641-6.
-
(2004)
Blood
, vol.103
, pp. 1641-1646
-
-
Dingli, D.1
Peng, K.W.2
Harvey, M.E.3
-
20
-
-
77953137806
-
Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers
-
Liu C, Russell SJ, Peng KW. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther 2010; 18 : 1155-64.
-
(2010)
Mol Ther
, vol.18
, pp. 1155-1164
-
-
Liu, C.1
Russell, S.J.2
Peng, K.W.3
-
22
-
-
74549226667
-
Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model
-
Lee JH, Roh MS, Lee YK, et al. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Cancer Gene Ther 2009; 17 : 73-9.
-
(2009)
Cancer Gene Ther
, vol.17
, pp. 73-79
-
-
Lee, J.H.1
Roh, M.S.2
Lee, Y.K.3
-
23
-
-
57649125119
-
An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors
-
Lei N, Shen FB, Chang JH, et al. An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors. Cancer Gene Ther 2009; 16 : 33-43.
-
(2009)
Cancer Gene Ther
, vol.16
, pp. 33-43
-
-
Lei, N.1
Shen, F.B.2
Chang, J.H.3
-
24
-
-
73449144100
-
Buy one get one free: Armed viruses for the treatment of cancer cells and their microenvironment
-
Kaur B, Cripe TP, Chiocca EA. "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther 2009; 9 : 341-55.
-
(2009)
Curr Gene Ther
, vol.9
, pp. 341-355
-
-
Kaur, B.1
Cripe, T.P.2
Chiocca, E.A.3
-
25
-
-
0037345805
-
Neoadjuvant treatment of hepatic malignancy: An oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection
-
Jarnagin WR, Zager JS, Klimstra D, et al. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection. Cancer Gene Ther 2003; 10 : 215-23.
-
(2003)
Cancer Gene Ther
, vol.10
, pp. 215-223
-
-
Jarnagin, W.R.1
Zager, J.S.2
Klimstra, D.3
-
26
-
-
1642535483
-
Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12
-
Wong RJ, Chan MK, Yu Z, et al. Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 2004; 10 : 251-9.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 251-259
-
-
Wong, R.J.1
Chan, M.K.2
Yu, Z.3
-
27
-
-
32844475008
-
Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers
-
Varghese S, Rabkin SD, Liu R, et al. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther 2006; 13 : 253-65.
-
(2006)
Cancer Gene Ther
, vol.13
, pp. 253-265
-
-
Varghese, S.1
Rabkin, S.D.2
Liu, R.3
-
28
-
-
0034050884
-
Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors
-
Parker JN, Gillespie GY, Love CE, et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA 2000; 97 : 2208-13.
-
(2000)
Proc Natl Acad Sci USA
, vol.97
, pp. 2208-2213
-
-
Parker, J.N.1
Gillespie, G.Y.2
Love, C.E.3
-
29
-
-
76349109690
-
Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL
-
Huang JH, Zhang SN, Choi KJ, et al. Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol Ther 2010; 18 : 264-74.
-
(2010)
Mol Ther
, vol.18
, pp. 264-274
-
-
Huang, J.H.1
Zhang, S.N.2
Choi, K.J.3
-
30
-
-
28244502278
-
Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system
-
Fukuhara H, Ino Y, Kuroda T, et al. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res 2005; 65 : 10663-8.
-
(2005)
Cancer Res
, vol.65
, pp. 10663-10668
-
-
Fukuhara, H.1
Ino, Y.2
Kuroda, T.3
-
31
-
-
84855968515
-
Potentiating cancer immunotherapy using an oncolytic virus
-
Bridle BW, Stephenson KB, Boudreau JE, et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther 2010; 184 : 4269-75.
-
(2010)
Mol Ther
, vol.184
, pp. 4269-4275
-
-
Bridle, B.W.1
Stephenson, K.B.2
Boudreau, J.E.3
-
32
-
-
77953479211
-
Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer
-
Castelo-Branco P, Passer BJ, Buhrman JS, et al. Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer. Gene Ther 2010; 17 : 805-10.
-
(2010)
Gene Ther
, vol.17
, pp. 805-810
-
-
Castelo-Branco, P.1
Passer, B.J.2
Buhrman, J.S.3
-
33
-
-
76349112703
-
Intelligent design: Combination therapy with oncolytic viruses
-
Ottolino-Perry K, Diallo JS, Lichty BD, et al. Intelligent design: combination therapy with oncolytic viruses. Mol Ther 2010; 18 : 251-63.
-
(2010)
Mol Ther
, vol.18
, pp. 251-263
-
-
Ottolino-Perry, K.1
Diallo, J.S.2
Lichty, B.D.3
-
34
-
-
77951987824
-
Synergistic interaction between oncolytic viruses augments tumor killing
-
Le Boeuf F, Diallo JS, McCart JA, et al. Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther 2010; 18 : 888-95.
-
(2010)
Mol Ther
, vol.18
, pp. 888-895
-
-
Le Boeuf, F.1
Diallo, J.S.2
McCart, J.A.3
-
35
-
-
77953544825
-
Oncolytic viruses and histone deacetylase inhibitors-A multi-pronged strategy to target tumor cells
-
Nguyen TL, Wilson MG, Hiscott J. Oncolytic viruses and histone deacetylase inhibitors-a multi-pronged strategy to target tumor cells. Cytokine Growth Factor Rev 2010; 21 : 153-9.
-
(2010)
Cytokine Growth Factor Rev
, vol.21
, pp. 153-159
-
-
Nguyen, T.L.1
Wilson, M.G.2
Hiscott, J.3
-
36
-
-
0032814773
-
Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses
-
Ikeda K, Ichikawa T, Wakimoto H, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999; 5 : 881-7.
-
(1999)
Nat Med
, vol.5
, pp. 881-887
-
-
Ikeda, K.1
Ichikawa, T.2
Wakimoto, H.3
-
37
-
-
77953135826
-
A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers
-
Diallo JS, Le Boeuf F, Lai F, et al. A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol Ther 2010; 18 : 1123-9.
-
(2010)
Mol Ther
, vol.18
, pp. 1123-1129
-
-
Diallo, J.S.1
Le Boeuf, F.2
Lai, F.3
-
38
-
-
77952869168
-
Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication
-
Passer BJ, Cheema T, Zhou B, et al. Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Res 2010; 70 : 3890-5.
-
(2010)
Cancer Res
, vol.70
, pp. 3890-3895
-
-
Passer, B.J.1
Cheema, T.2
Zhou, B.3
-
40
-
-
80052406557
-
Intravenous delivery of a multimechanistic cancer-targeted oncolytic poxvirus in humans
-
Breitbach CJ, Burke J, Jonker D, et al. Intravenous delivery of a multimechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011; 477 : 99-102.
-
(2011)
Nature
, vol.477
, pp. 99-102
-
-
Breitbach, C.J.1
Burke, J.2
Jonker, D.3
-
41
-
-
84860870216
-
Le virus de la rougeole - Un futur traitement en cancérologie ?
-
Touchefeu Y, Schick U, Harrington KJ. Le virus de la rougeole - Un futur traitement en cancérologie ? Med Sci (Paris) 2012; 28 : 388-94.
-
(2012)
Med Sci (Paris)
, vol.28
, pp. 388-394
-
-
Touchefeu, Y.1
Schick, U.2
Harrington, K.J.3
-
42
-
-
84860868454
-
Apprivoiser nos ennemis pour en faire des alliés : la « virothérapie » anticancéreuse
-
Lemay G. Apprivoiser nos ennemis pour en faire des alliés : la « virothérapie » anticancéreuse. Med Sci (Paris) 2012; 28 : 339-40.
-
(2012)
Med Sci (Paris)
, vol.28
, pp. 339-340
-
-
Lemay, G.1
-
43
-
-
84874712759
-
Le virus de la stomatite vésiculaire dans la lutte contre le cancer
-
Janelle V, Poliquin L, Lamarre A. Le virus de la stomatite vésiculaire dans la lutte contre le cancer. Med Sci (Paris) 2013, 29 : 175-82.
-
(2013)
Med Sci (Paris)
, vol.29
, pp. 175-182
-
-
Janelle, V.1
Poliquin, L.2
Lamarre, A.3
|